Visual results following intravitreal bevacizumab in neovascular age-related macular degeneration

Journal of the College of Physicians and Surgeons Pakistan

Volumn 21, Issue 9, 2011, Pages 535-538

  Iqbal, Kashif ^a   Baig, Jamil ^a   Jamil, Ahmad Zeeshan ^a   Jamil, Hannan ^a   Mirza, Khurram ^a   Khan, Tariq ^a  

^a Layton Rahmatulla Benevolent Trust Eye Hospital (LRBT)   (Pakistan)

Author keywords

Age related macular degeneration; Bevacizumab; Choroidal neovascularization; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CORNEA THICKNESS; DIASTOLIC BLOOD PRESSURE; ENDOPHTHALMITIS; EXUDATIVE MACULAR DEGENERATION; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; QUASI EXPERIMENTAL STUDY; RETINA DETACHMENT; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; SYSTOLIC BLOOD PRESSURE; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADULT; AGE FACTORS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD PRESSURE; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 80052771986     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102:1640-2.
2. Kanski JJ. Clinical ophthalmology: a systematic approach. 6 ed. London: Butterworth-Heinemann; 2006.
3. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in agerelated maculopathy. Br J Ophthalmol 1997; 81:154-62.
4. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18:4-25.
5. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Michaud NA, Li W, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002; 120:338-46.
6. Gragoudas ES, Adamis AP, Cunnighman ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351:2805-16.
7. Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006; 113:633e1-4. Epub 2006 Feb 14.
8. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature 2004; 3:391-400.
9. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112:1035-47.
10. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-372.e5. Epub 2006 Feb 3.
11. Miller JW, Chung CY, Kim R. Randomized, controlled phase III study of ranibizumab [lucentis] for minimally classic or occult neovascular age-related macular degeneration. Canada: American Society of Retinal Specialists; 2005.
12. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36:331-5.
13. Wong D, Li KK. Avastin in myopic choroidal neovascularisation: is age the limit? Br J Ophthalmol 2008; 92:1011-2.
14. Rosiak J, Sadowski L. Hypertension associated with bevacizumab. Clin J Oncol Nurs 2005; 9:407-11.
15. Naeem Ullah, Butt NH, Shafique MM, Huma K, Ahmad A, Qandeel. Treatment of age-related macular degeneration (AMD)- A trial with dietry supplement of vitamins and minerals. Pak J Ophthalmol 2003; 19:9-13.